• Markets
    • icon
  • Companies
PAR · ASX

Paradigm Biopharmaceuticals Ltd. (ASX:PAR)

AU$0.4

 0.005 (1.266%)
ASX:Live
04/12/2023 04:10:48 PM
Hammer Bearish HALO Ords HALO Consensus Value GROWTH AUS All-Consensus +1
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PAR Overview

PAR Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About PAR

Website

Paradigm Biopharmaceuticals Ltd.

Telephone

61.3.9629.5566

Address

Level 15 500 Collins Street Melbourne, Victoria (VIC) 3000

Description

Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. It is a drug repurposing company which seeks to find new uses for old drugs. The company was founded by Paul John Rennie on May 2, 2014 and is headquartered in Melbourne, Australia.

PAR Price Chart

Key Stats

Market Cap

AU$120.87M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.38 - 1.68

Trade Value (12mth)

AU$151,590.00

1 week

1.28%

1 month

-8.14%

YTD

-71.4%

1 year

-71.99%

All time high

4.3453

Key Fundamentals

EPS 3 yr Growth

195.200%

EBITDA Margin

%

Operating Cashflow

-$45m

Free Cash Flow Return

-93.50%

ROIC

-107.40%

Interest Coverage

-3,597.80

Quick Ratio

4.90

Other Data

Shares on Issue (Fully Dilluted)

290m

HALO Sector

Healthcare

Next Company Report Date

23-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

1.28

PAR Announcements

Latest Announcements

Date Announcements

31 October 23

PAR Successful Placement and Fully Underwritten ANREO

×

PAR Successful Placement and Fully Underwritten ANREO

31 October 23

Replacement Entitlement Offer and Placement Prospectus

×

Replacement Entitlement Offer and Placement Prospectus

31 October 23

Update - Proposed issue of securities - PAR

×

Update - Proposed issue of securities - PAR

31 October 23

Proposed issue of securities - PAR

×

Proposed issue of securities - PAR

31 October 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 March 23

Trading Halt

×

Trading Halt

31 July 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 23

Application for quotation of securities - PAR

×

Application for quotation of securities - PAR

31 January 22

Quarterly Update and Appendix 4C - quarterly

×

Quarterly Update and Appendix 4C - quarterly

30 September 22

Trading Halt

×

Trading Halt

30 October 23

Trading Halt

×

Trading Halt

30 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

30 October 23

Paradigm Launches $30M Capital Raising

×

Paradigm Launches $30M Capital Raising

30 October 23

Investor Presentation - $30m Capital Raise

×

Investor Presentation - $30m Capital Raise

30 October 23

Proposed issue of securities - PAR

×

Proposed issue of securities - PAR

30 October 23

Entitlement Offer and Placement Prospectus

×

Entitlement Offer and Placement Prospectus

30 October 23

Update - Proposed issue of securities - PAR

×

Update - Proposed issue of securities - PAR

30 October 15

CEO AGM Presentation

×

CEO AGM Presentation

30 November 23

Application for quotation of securities - PAR

×

Application for quotation of securities - PAR

30 November 23

Notification of cessation of securities - PAR

×

Notification of cessation of securities - PAR

30 November 23

Change of Director's Interest Notice - Rennie

×

Change of Director's Interest Notice - Rennie

30 November 16

Managing Director's Presentation to AGM

×

Managing Director's Presentation to AGM

30 November 16

Results of Annual General Meeting

×

Results of Annual General Meeting

30 May 22

Paradigm Appoints Experienced US-Based CEO

×

Paradigm Appoints Experienced US-Based CEO

30 June 22

Paradigm Reports Australian Patent Acceptance

×

Paradigm Reports Australian Patent Acceptance

30 December 22

Notification of cessation of securities - PAR

×

Notification of cessation of securities - PAR

30 August 22

Paradigm Appoints Interim Company Secretary

×

Paradigm Appoints Interim Company Secretary

PAR Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.17 -0.17 -0.18 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.17 -0.17 -0.18 Lock Lock Lock
     Growth % Lock Lock Lock Lock -173.8 -0.8 -7.0 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.13 -0.16 -0.17 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.17 -0.14 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -182.1 -16.1 -11.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -8.1 -14.3 0.0 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.34 0.18 0.19 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.33 0.17 0.18 Lock Lock Lock
     Growth % Lock Lock Lock Lock -30.0 -48.4 4.3 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 206 235 290 Lock Lock Lock
Basic m Lock Lock Lock Lock 206 234 290 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A 285.5 -41.0 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 42 47 59 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -35.4 10.7 51.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,404.6 -325.4 -268.9 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 1,505 425 369 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -42 -47 -59 Lock Lock Lock
     Growth % Lock Lock Lock Lock -151.6 -11.1 -26.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -205,029.8 -59,095.0 -126,309.1 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -42 -47 -59 Lock Lock Lock
     Growth % Lock Lock Lock Lock -149.7 -11.0 -26.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -206,052.0 -59,339.0 -126,637.7 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -43 -47 -59 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -8 -8 -7 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -34 -39 -52 Lock Lock Lock
     Growth % Lock Lock Lock Lock -178.9 -14.4 -32.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -166,896.3 -49,542.5 -111,013.7 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -35 -32 -45 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 1 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 1 0 63 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -35 -32 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -242.2 7.9 100.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,701.2 -406.5 0.0 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 71 40 56 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 85 51 67 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -70 -39 -56 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 7 8 13 Lock Lock Lock
Equity $m Lock Lock Lock Lock 78 42 54 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 79 43 54 Lock Lock Lock
     Growth % Lock Lock Lock Lock -27.6 -45.8 26.0 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -40.4 -77.4 -77.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -43.8 -92.8 -96.7 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -45.0 -77.1 -122.2 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -36.5 -64.5 -107.4 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -37.2 -52.9 -93.5 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -1,117.0 -1,635.1 -3,597.8 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.7 0.8 0.9 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -89.9 -92.4 -104.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 14.0 6.0 4.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 14.0 6.0 4.9 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 87.8 84.2 88.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -602.9 -411.3 -346.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 24,264.9 8,947.1 26,007.7 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -207,522.6 -59,340.8 -126,074.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -50.3 -92.7 -87.9 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -40.4 -77.4 -77.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.2 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -43.8 -92.8 -96.7 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -43.8 -92.8 -96.7 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 106,724.0 35,075.5 52,791.1 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 106,724.0 35,075.5 52,791.1 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 4,562.5 6,541.2 20,391.1 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 102,161.5 28,534.3 32,400.1 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

1.28%

Value ($M)

2

Prior Change

-0.80%

7 Day Change

N/A

1 Month Change

-0.70%

3 Month Change

-0.20%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PAR Shortsell

Frequently Asked Questions

The current share price of Paradigm Biopharmaceuticals Ltd. (PAR:ASX) is AU$0.4.
The 52-week high share price for Paradigm Biopharmaceuticals Ltd. (PAR:ASX) is AU$1.68.
The 52-week low share price for Paradigm Biopharmaceuticals Ltd. (PAR:ASX)? is AU$0.38.
Paradigm Biopharmaceuticals Ltd. (PAR:ASX) does not pay a dividend.
Paradigm Biopharmaceuticals Ltd. (PAR:ASX) does not pay a dividend.
Paradigm Biopharmaceuticals Ltd. (PAR:ASX) has a franking level of 0%.
Paradigm Biopharmaceuticals Ltd. (PAR:ASX) is classified in the Healthcare.
The current P/E ratio for Paradigm Biopharmaceuticals Ltd. (PAR:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.